Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan
Abstract Introduction Comprehensive genome profiling (CGP) has revolutionized healthcare by offering personalized medicine opportunities. However, its real‐world utility and impact remain incompletely understood. This study examined the extent to which CGP leads to genomically matched therapy and it...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-09-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70249 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849688993577304064 |
|---|---|
| author | Kei Kunimasa Naotoshi Sugimoto Tomoyuki Yamasaki Yoji Kukita Fumie Fujisawa Tazuko Inoue Yuko Yamaguchi Mitsuko Kitasaka Daisuke Sakai Keiichiro Honma Toru Wakamatsu Sachiko Yamamoto Takuji Hayashi Seiji Mabuchi Jun Okuno Takahisa Kawamura Yugo Kai Makiko Urabe Kazuo Nishimura |
| author_facet | Kei Kunimasa Naotoshi Sugimoto Tomoyuki Yamasaki Yoji Kukita Fumie Fujisawa Tazuko Inoue Yuko Yamaguchi Mitsuko Kitasaka Daisuke Sakai Keiichiro Honma Toru Wakamatsu Sachiko Yamamoto Takuji Hayashi Seiji Mabuchi Jun Okuno Takahisa Kawamura Yugo Kai Makiko Urabe Kazuo Nishimura |
| author_sort | Kei Kunimasa |
| collection | DOAJ |
| description | Abstract Introduction Comprehensive genome profiling (CGP) has revolutionized healthcare by offering personalized medicine opportunities. However, its real‐world utility and impact remain incompletely understood. This study examined the extent to which CGP leads to genomically matched therapy and its effectiveness. Methods We analyzed data from advanced solid tumor patients who underwent CGP panel between December 2019 and May 2023 at the Osaka International Cancer Institute. Patient demographics, specimen details, and expert panel assessments were collected. Turnaround time (TAT) and genomically matched therapy outcomes were analyzed. Gene alterations and their co‐occurrence patterns were also assessed. Results Among 1437 patients, 1096 results were available for analysis. The median TAT was 63 [28–182] days. There were 667 (60.9%) cases wherein recommended clinical trials were presented and there were 12 (1.1%) cases that could be enrolled in the trial and 25 (2.3%) cases that could lead to therapies under insurance reimbursement. The median progression free survival of the trial treatment was 1.58 months (95% CI: 0.66–4.37) in clinical trials and 3.66 months (95% CI: 2.14–7.13) in treatment under insurance. Pathologic germline variants were confirmed in 15 patients (1.3%). Co‐alteration of CDKN2A, CDKN2B, and MTAP was significantly observed in overall population. Conclusion The effectiveness of the genomically matched therapy based on the CGP panel was unsatisfactory. Expansion of clinical trials and utilization of remote clinical trials are required to ensure that the results of the CGP panel can be fully returned to patients. |
| format | Article |
| id | doaj-art-53191da167c842a595bde87157a3ece0 |
| institution | DOAJ |
| issn | 2045-7634 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-53191da167c842a595bde87157a3ece02025-08-20T03:21:47ZengWileyCancer Medicine2045-76342024-09-011318n/an/a10.1002/cam4.70249Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in JapanKei Kunimasa0Naotoshi Sugimoto1Tomoyuki Yamasaki2Yoji Kukita3Fumie Fujisawa4Tazuko Inoue5Yuko Yamaguchi6Mitsuko Kitasaka7Daisuke Sakai8Keiichiro Honma9Toru Wakamatsu10Sachiko Yamamoto11Takuji Hayashi12Seiji Mabuchi13Jun Okuno14Takahisa Kawamura15Yugo Kai16Makiko Urabe17Kazuo Nishimura18Department of Thoracic Oncology Osaka International Cancer Institute Osaka JapanDepartment of Genetic Oncology Osaka International Cancer Institute Osaka JapanDepartment of Genetic Oncology Osaka International Cancer Institute Osaka JapanDepartment of Genetic Oncology Osaka International Cancer Institute Osaka JapanDepartment of Genetic Oncology Osaka International Cancer Institute Osaka JapanDepartment of Genetic Oncology Osaka International Cancer Institute Osaka JapanDepartment of Genetic Oncology Osaka International Cancer Institute Osaka JapanDepartment of Genetic Oncology Osaka International Cancer Institute Osaka JapanDepartment of Genetic Oncology Osaka International Cancer Institute Osaka JapanDepartment of Diagnostic Pathology and Cytology Osaka International Cancer Institute Osaka JapanMusculoskeletal Oncology Service Osaka International Cancer Institute Osaka JapanDepartment of Gastrointestinal Oncology Osaka International Cancer Institute Osaka JapanDepartment of Urology Osaka International Cancer Institute Osaka JapanDepartment of Gynecology Osaka International Cancer Institute Osaka JapanDepartment of Breast and Endocrine Surgery Osaka International Cancer Institute Osaka JapanDepartment of Thoracic Oncology Osaka International Cancer Institute Osaka JapanDepartment of Hepatobiliary and Pancreatic Oncology Osaka International Cancer Institute Osaka JapanDepartment of Hepatobiliary and Pancreatic Oncology Osaka International Cancer Institute Osaka JapanDepartment of Genetic Oncology Osaka International Cancer Institute Osaka JapanAbstract Introduction Comprehensive genome profiling (CGP) has revolutionized healthcare by offering personalized medicine opportunities. However, its real‐world utility and impact remain incompletely understood. This study examined the extent to which CGP leads to genomically matched therapy and its effectiveness. Methods We analyzed data from advanced solid tumor patients who underwent CGP panel between December 2019 and May 2023 at the Osaka International Cancer Institute. Patient demographics, specimen details, and expert panel assessments were collected. Turnaround time (TAT) and genomically matched therapy outcomes were analyzed. Gene alterations and their co‐occurrence patterns were also assessed. Results Among 1437 patients, 1096 results were available for analysis. The median TAT was 63 [28–182] days. There were 667 (60.9%) cases wherein recommended clinical trials were presented and there were 12 (1.1%) cases that could be enrolled in the trial and 25 (2.3%) cases that could lead to therapies under insurance reimbursement. The median progression free survival of the trial treatment was 1.58 months (95% CI: 0.66–4.37) in clinical trials and 3.66 months (95% CI: 2.14–7.13) in treatment under insurance. Pathologic germline variants were confirmed in 15 patients (1.3%). Co‐alteration of CDKN2A, CDKN2B, and MTAP was significantly observed in overall population. Conclusion The effectiveness of the genomically matched therapy based on the CGP panel was unsatisfactory. Expansion of clinical trials and utilization of remote clinical trials are required to ensure that the results of the CGP panel can be fully returned to patients.https://doi.org/10.1002/cam4.70249clinical trialcomprehensive genomic profilinggenomically matched therapyreal world datasolid tumor |
| spellingShingle | Kei Kunimasa Naotoshi Sugimoto Tomoyuki Yamasaki Yoji Kukita Fumie Fujisawa Tazuko Inoue Yuko Yamaguchi Mitsuko Kitasaka Daisuke Sakai Keiichiro Honma Toru Wakamatsu Sachiko Yamamoto Takuji Hayashi Seiji Mabuchi Jun Okuno Takahisa Kawamura Yugo Kai Makiko Urabe Kazuo Nishimura Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan Cancer Medicine clinical trial comprehensive genomic profiling genomically matched therapy real world data solid tumor |
| title | Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan |
| title_full | Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan |
| title_fullStr | Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan |
| title_full_unstemmed | Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan |
| title_short | Real‐world assessment of comprehensive genome profiling impact on clinical outcomes: A single‐institution study in Japan |
| title_sort | real world assessment of comprehensive genome profiling impact on clinical outcomes a single institution study in japan |
| topic | clinical trial comprehensive genomic profiling genomically matched therapy real world data solid tumor |
| url | https://doi.org/10.1002/cam4.70249 |
| work_keys_str_mv | AT keikunimasa realworldassessmentofcomprehensivegenomeprofilingimpactonclinicaloutcomesasingleinstitutionstudyinjapan AT naotoshisugimoto realworldassessmentofcomprehensivegenomeprofilingimpactonclinicaloutcomesasingleinstitutionstudyinjapan AT tomoyukiyamasaki realworldassessmentofcomprehensivegenomeprofilingimpactonclinicaloutcomesasingleinstitutionstudyinjapan AT yojikukita realworldassessmentofcomprehensivegenomeprofilingimpactonclinicaloutcomesasingleinstitutionstudyinjapan AT fumiefujisawa realworldassessmentofcomprehensivegenomeprofilingimpactonclinicaloutcomesasingleinstitutionstudyinjapan AT tazukoinoue realworldassessmentofcomprehensivegenomeprofilingimpactonclinicaloutcomesasingleinstitutionstudyinjapan AT yukoyamaguchi realworldassessmentofcomprehensivegenomeprofilingimpactonclinicaloutcomesasingleinstitutionstudyinjapan AT mitsukokitasaka realworldassessmentofcomprehensivegenomeprofilingimpactonclinicaloutcomesasingleinstitutionstudyinjapan AT daisukesakai realworldassessmentofcomprehensivegenomeprofilingimpactonclinicaloutcomesasingleinstitutionstudyinjapan AT keiichirohonma realworldassessmentofcomprehensivegenomeprofilingimpactonclinicaloutcomesasingleinstitutionstudyinjapan AT toruwakamatsu realworldassessmentofcomprehensivegenomeprofilingimpactonclinicaloutcomesasingleinstitutionstudyinjapan AT sachikoyamamoto realworldassessmentofcomprehensivegenomeprofilingimpactonclinicaloutcomesasingleinstitutionstudyinjapan AT takujihayashi realworldassessmentofcomprehensivegenomeprofilingimpactonclinicaloutcomesasingleinstitutionstudyinjapan AT seijimabuchi realworldassessmentofcomprehensivegenomeprofilingimpactonclinicaloutcomesasingleinstitutionstudyinjapan AT junokuno realworldassessmentofcomprehensivegenomeprofilingimpactonclinicaloutcomesasingleinstitutionstudyinjapan AT takahisakawamura realworldassessmentofcomprehensivegenomeprofilingimpactonclinicaloutcomesasingleinstitutionstudyinjapan AT yugokai realworldassessmentofcomprehensivegenomeprofilingimpactonclinicaloutcomesasingleinstitutionstudyinjapan AT makikourabe realworldassessmentofcomprehensivegenomeprofilingimpactonclinicaloutcomesasingleinstitutionstudyinjapan AT kazuonishimura realworldassessmentofcomprehensivegenomeprofilingimpactonclinicaloutcomesasingleinstitutionstudyinjapan |